Open Access Research article

Impact of evergreening on patients and health insurance: a meta analysis and reimbursement cost analysis of citalopram/escitalopram antidepressants

Ali A Alkhafaji12, Ludovic Trinquart1234, Gabriel Baron12, Moïse Desvarieux256 and Philippe Ravaud123456*

Author Affiliations

1 Centre d'Epidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 1 place du parvis Notre Dame, Paris, 75004, France

2 INSERM U738, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris, 1 place du parvis Notre Dame, Paris, 75004, France

3 Université Paris Descartes - Sorbonne Paris Cité, 12 Rue de l'École de Médecine Paris, 75006, France

4 French Cochrane Centre, Hôpital Hôtel-Dieu, 1 place du parvis Notre Dame, Paris, 75004, France

5 EHESP School of Public Health, Avenue du Professeur Léon-Bernard, CS 74312, Rennes, 35043, France

6 Department of Epidemiology, Columbia University Mailman School of Public Health, 722 West 168th Street, New York, NY 10032, USA

For all author emails, please log on.

BMC Medicine 2012, 10:142  doi:10.1186/1741-7015-10-142

Published: 20 November 2012

Additional files

Additional file 1:

Section 1: Selection criteria and search strategy. Section 2: Methods and analysis details. Section 3: Selected trials. Section 4: Network analysis of trials for direct and indirect comparison and the number of trials in each comparison. Section 5: Characteristics of trials. Section 6: Characteristics of trials across different comparisons. Section 7: Consumption and cost analyses for the citalopram, generic citalopram, escitalopram from the French national health insurance information system. Section 8: Meta-analysis for efficacy data of head-to-head trials. Section 9: Funnel plot for efficacy data for head-to-head trials. Section 10: Meta-analysis for acceptability data for head-to-head trials. Section 11: Meta-analysis for efficacy data for placebo-controlled trials. Section 12: Funnel plot for efficacy data for placebo-controlled trials. Section 13: Meta-analysis for acceptability data for placebo-controlled trials. Section 14: Consumption levels (monthly no. of prescriptions) between 2003 and 2011 in France. Section 15: Consumption levels (monthly defined daily dose (DDD) units) between 2003 and 2011 in France. Section 16: Consumption levels for escitalopram versus citalopram and its generic forms combined. Section 17: Total consumption of escitalopram, citalopram and its generic forms.

Format: DOCX Size: 143KB Download file

Open Data